Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1991 1
1993 2
1995 1
1999 1
2001 2
2006 1
2007 1
2008 1
2010 1
2011 2
2012 1
2013 7
2014 1
2015 2
2016 6
2017 22
2018 20
2019 17
2020 5
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 32392516

87 results
Results by year
Filters applied: . Clear all
Page 1
Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics.
Breiner A, Zinman L, Bourque PR. Breiner A, et al. CMAJ. 2020 Mar 23;192(12):E319-E320. doi: 10.1503/cmaj.191236. CMAJ. 2020. PMID: 32392516 Free PMC article. No abstract available.
Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.
Luo L, Song Z, Li X, Huiwang, Zeng Y, Qinwang, Meiqi, He J. Luo L, et al. Neurol Sci. 2019 Feb;40(2):235-241. doi: 10.1007/s10072-018-3653-2. Epub 2018 Nov 27. Neurol Sci. 2019. PMID: 30483992
Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis.
Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y. Okada M, et al. eNeurologicalSci. 2018 May 17;11:11-14. doi: 10.1016/j.ensci.2018.05.001. eCollection 2018 Jun. eNeurologicalSci. 2018. PMID: 29928711 Free PMC article.
Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Brooks BR, et al. Am J Manag Care. 2018 Apr;24(9 Suppl):S175-S186. Am J Manag Care. 2018. PMID: 29693363 Free article. Review.
Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Bhandari R, Kuhad A, Kuhad A. Bhandari R, et al. Drugs Today (Barc). 2018 Jun;54(6):349-360. doi: 10.1358/dot.2018.54.6.2828189. Drugs Today (Barc). 2018. PMID: 29998226 Review.
Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP. WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):55-63. doi: 10.1080/21678421.2017.1364269. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872920 Clinical Trial.
Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP. WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):20-31. doi: 10.1080/21678421.2017.1362000. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872918 Clinical Trial.
Edaravone and its clinical development for amyotrophic lateral sclerosis.
Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Takei K, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):5-10. doi: 10.1080/21678421.2017.1353101. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872907 Review.
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H; Edaravone ALS Study Group. Abe K, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7. doi: 10.3109/21678421.2014.959024. Epub 2014 Oct 6. Amyotroph Lateral Scler Frontotemporal Degener. 2014. PMID: 25286015 Free PMC article. Clinical Trial.
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Jaiswal MK. Jaiswal MK. Med Res Rev. 2019 Mar;39(2):733-748. doi: 10.1002/med.21528. Epub 2018 Aug 12. Med Res Rev. 2019. PMID: 30101496 Review.
87 results
Jump to page
Feedback